<DOC>
	<DOCNO>NCT00500123</DOCNO>
	<brief_summary>The Alpha-1 Coded Testing ( ACT ) Study establish study genetic test outcomes individual risk alpha-1 antitrypsin deficiency .</brief_summary>
	<brief_title>Alpha-1 Coded Testing ( ACT ) Study</brief_title>
	<detailed_description>Genetic test alpha-1 antitrypsin deficiency sometimes delay despite establish test indication . All genetic test risk possible benefit . The ACT study evaluate population demographic , reason test , outcomes confidential test program . Co-morbidities alpha-1 antitrypsin deficiency lung liver disease investigate . Concerns genetic confidentiality lessen study cod test procedure return result mail study participant .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Individuals age risk alpha1 antitrypsin deficiency basis symptom family genetic risk .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>alpha-1</keyword>
	<keyword>antitrypsin</keyword>
	<keyword>AAT</keyword>
	<keyword>genetic testing</keyword>
	<keyword>alpha-1 antitrypsin deficiency</keyword>
	<keyword>AATD</keyword>
</DOC>